文献速递儿童血液肿瘤与免疫

改良CCLG-AML2019方案治疗儿童急性髓系白血病的临床分析

[Clinical analysis of modified Chinese Children Leukemia Group-Acute Myeloid Leukemia 2019 regimen in treating pediatric acute myeloid leukemia].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2026-10-15

回顾性分析41例初诊非APL的AML患儿,均接受CCLG-AML2019方案化疗,高危患儿第三疗程引入含克拉屈滨强化挽救方案。整体5年OS为85±7%、EFS为79±7%,非高危组均100%,高危组分别为75±10%和65±11%,两组EFS差异有统计学意义(P=0.018)。

要点

  • CCLG-AML2019改良方案治疗儿童非APL的AML可获得良好短期生存,非高危患儿尤佳。
  • 高危患儿allo-HSCT后仍面临复发和移植相关死亡风险。
  • CBF-AML整体预后良好,高频KIT基因变异未抵消其有利影响。

核心结论

  • CCLG-AML2019改良方案治疗儿童非APL的AML可获得良好短期生存获益,尤其非高危患儿;高危患儿接受allo-HSCT后仍面临复发和移植相关死亡风险。

研究设计与样本

  • 回顾性队列研究纳入2019年11月至2023年12月首都医科大学附属首都儿童医学中心收治的41例初诊非APL的AML患儿,分析性别、年龄、FAB分型、遗传学、分子学、治疗、疗效及预后。

主要发现

  • 41例患儿中男22例、女19例,诊断年龄5.8(2.6,8.0)岁,高危组24例(59%),非高危组17例(41%),随访51(38,62)个月。
  • 整体5年OS率为(85±7)%,5年EFS率为(79±7)%;非高危组均为100%,高危组分别为(75±10)%和(65±11)%,两组EFS差异有统计学意义(P=0.018)。
  • <2岁组共10例,FAB分型以M5或M7为主共9例,KMT2A基因重排阳性者5例,高危患儿8例。
  • 核心结合因子相关AML 19例,其中KIT基因变异者10例,无白血病复发;随访期间死亡5例,因白血病复发、移植相关死亡各2例,感染致死1例。

关键数值与推荐

  • 高危患儿于3或4个疗程后行allo-HSCT;针对诱导治疗后MRD持续高水平的高危患儿,第三疗程引入含克拉屈滨的强化挽救化疗方案。

临床怎么用

  • 儿童非APL的AML可采用CCLG-AML2019改良方案化疗,高危患儿按计划行allo-HSCT并关注复发和移植相关死亡风险。
  • <2岁患儿可考虑化学治疗联合靶向药物治疗;CBF-AML整体预后良好,KIT基因变异高频不影响其有利预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical efficiency and prognosis of a modified regimen based on the Chinese Children Leukemia Group-Acute Myeloid Leukemia 2019 (CCLG-AML2019) protocol for childhood acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia, non-APL). Methods: In this retrospective cohort study, clinical data including sex, age, French-American-British (FAB) classification, genetics, molecular biology, treatment, therapeutic efficacy and prognosis of 41 newly diagnosed non-APL AML children treated at Capital Institute of Pediatrics, Capital Pediatric Medical Center, Capital Medical University from November 2019 to December 2023 were analyzed. All children received chemotherapy according to the CCLG-AML2019 protocol. For high-risk (HR) children with persistent high-level minimal residual disease (MRD) after induction therapy, a cladribine-containing intensified salvage chemotherapy regimen was introduced in the third course. According to the risk stratification criteria, children were divided into high-risk and non-high-risk groups. High-risk children received allogeneic hematopoietic stem cell transplantation (allo-HSCT) after 3 or 4 courses of chemotherapy. Children were divided into two groups according to age (<2 years and ≥2 years group), and the clinical characteristics and prognosis between the two groups were compared using Fisher's exact test. Kaplan-Meier method was used to estimate the 5-year overall survival (OS) rate and event-free survival (EFS) rate, and Cox regression was employed for univariate analysis. Results: Among the 41 children, there were 22 males and 19 females, with an age of 5.8 (2.6, 8.0) years. Twenty-four children (59%) were classified as the high-risk group, and 17 (41%) as the non-high-risk group. The follow-up duration was 51(38, 62) months. The 5-year OS rate was (85±7)%, and the 5-year EFS rate was (79±7)%. Non-HR children achieved 100% for both, whereas in the high-risk group, the corresponding rates were (75±10)% and (65±11)%, respectively. The difference in EFS rate between the two groups had statistically difference (P=0.018). There were 10 children in the <2 years age group, among them FAB M5 or M7 subtypes were observed in 9 children, KMT2A gene rearrangements were observed in 5 children, and high-risk stratification were defined in 8 children. Core binding factor (CBF)-AML (19 children) had a KIT gene variation in 10 children, and with no relapse. During follow-up, 5 deaths occurred (2 due to relapse, 2 due to transplant-related complications, and 1 due to infection). Conclusions: The CCLG-AML2019 regimen offers favorable short-term survival for pediatric non-APL AML, especially in non-HR children. HR children still face the risks of relapse and transplant-related mortality after allo-HSCT. Children aged <2 years may benefit from chemotherapy combined with targeted therapy. CBF-AML has a favorable overall prognosis, and the high frequency of KIT gene variation did not attenuate this advantage. 目的: 探讨中国儿童白血病协作组(CCLG)-急性髓系白血病(AML)2019的改良方案治疗儿童急性髓系白血病(非急性早幼粒细胞白血病)的临床效果及预后。 方法: 回顾性队列研究,收集并分析2019年11月至2023年12月于首都医科大学附属首都儿童医学中心,首都儿科研究所收治的41例初诊非APL的AML患儿临床资料,包括性别、年龄、法美英(FAB)分型、遗传学、分子学、治疗、疗效及预后等。所有患儿均接受CCLG-AML2019方案化学治疗,在此基础上,针对诱导治疗后微小残留病变(MRD)持续高水平的高危患儿,在第三疗程中引入了含克拉屈滨的强化挽救化疗方案。根据危险度分层标准分为高危组与非高危组,高危患儿于3或4个疗程后行异基因造血干细胞移植(allo-HSCT)。根据发病年龄将患儿分为<2岁组和≥2岁组,采用Fisher确切概率法比较两组临床特征及预后。采用Kaplan-Meier法估算5年总生存率和无事件生存率,Cox回归进行单因素分析。 结果: 41例患儿中男22例、女19例,诊断年龄5.8(2.6,8.0)岁,高危组24例(59%),非高危组17例(41%)。随访51(38,62)个月。整体5年总生存率为(85±7)%,5年无事件生存率为(79±7)%;非高危组均为100%,高危组分别为(75±10)%和(65±11)%,两组无事件生存率差异有统计学意义(P=0.018)。<2岁组共10例,FAB分型以M5或M7为主共9例,KMT2A基因重排阳性者5例,高危患儿8例。核心结合因子相关AML 19例,其中KIT基因变异者10例,无白血病复发。随访期间死亡5例,因白血病复发、移植相关死亡各2例,感染致死1例。 结论: CCLG-AML2019的改良方案治疗儿童非APL的AML可获得良好的短期生存获益,尤其非高危患儿。高危患儿接受allo-HSCT后仍面临复发和移植相关死亡风险,<2岁患儿需考虑化学治疗联合靶向药物治疗。核心结合因子相关AML整体预后良好,高频KIT基因变异未抵消其有利影响。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Fan W, Li JJ, Zhang L, et al. [Clinical analysis of modified Chinese Children Leukemia Group-Acute Myeloid Leukemia 2019 regimen in treating pediatric acute myeloid leukemia]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42876096. doi:10.3760/cma.j.cn112140-20260828-00670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。